'Intrusive' cannabis farm noise affecting lives
The States of Jersey Complaints Panel upheld a complaint over how the Infrastructure and Environment Department handled residents' complaints about the noise and smells coming from the Northern Leaf farm in St Lawrence.
Roger Nightingale, who lives next to the site, said the noise emitted from the farm was so intrusive it meant he and his partner, Penny Bromley, could not sit in their garden.
Environment minister Steve Luce said the government strongly rejected the panel's findings and had put "a lot of resource" into the issues highlighted. The BBC has approached Northern Leaf for comment.
Mr Nightingale said a low level noise from the farm was aggravating to deal with.
"You can't sit in the garden for a length of time," he said. "There's low-level noise that gives you headaches so you can't have the windows open.
"It's really intrusive and affects your lifestyle."
Ms Bromley said the issues and "horrendous whirring sound" from the farm had forced her to spend more time away from Jersey.
"I can't enjoy my home at all," she said.
The panel said the government had taken too long to deal with complaints from residents.
It also criticised the government's use of an unjust "sniff test" to decide whether cannabis odours from the farm were a problem.
Ms Bromley added that the panel's comments had made complainants like her feel vindicated although she questioned whether it would "make much difference" overall.
"I think the farm's either got to be closed down or the noise has to be stopped," she said.
More news stories for Jersey
Listen to the latest news for Jersey
Deputy Hilary Jeune, chair of the environment, housing and infrastructure scrutiny panel, said the complaints had made it clear the island needed an independent public service ombudsman.
"We have seen the panel uphold the complaints but the government has pushed back on the recommendations," she said.
"The panel doesn't have any power to go further than that."
In response to the panel's findings, chief officer of infrastructure and environment Andy Scate said the government "completely refute the suggestion that the department acted contrary to the law or behaved in a way that was unjust".
Luce said the government had put in "thousands of hours" of work for years to deal with issues from residents' complaints about the farm.
"Unfortunately, we are in a process which becomes protracted and involves appeals, courts and a whole range of things," he said.
"But we have to be fair to both sides."
Follow BBC Jersey on X and Facebook. Send your story ideas to channel.islands@bbc.co.uk.
States panel upholds cannabis farm complaint
Cannabis site ordered to remove unauthorised kit
Jersey States votes not to decriminalise cannabis
States of Jersey
Government of Jersey
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Your Food Packaging Is Shedding Microplastics Into Every Meal, Study Reveals
Simply using your food packaging in the manner it's supposed to be used is enough to contaminate your comestibles with a sprinkling of microplastics. A painstaking review of 103 scientific studies on microplastic food contamination found actions as simple as opening a plastic drink bottle or using a plastic chopping board can shave off tiny particles of common polymers. Even glass bottles that use a plastic gasket, plastic-lined pizza boxes, plastic-lined disposable coffee cups, plastic tea bags, plastic wrappings, and microwaveable plastic containers shed microplastic like a Persian cat sheds fur in spring. The problem, a team led by biologist Lisa Zimmermann of the non-profit Food Packaging Forum in Switzerland says, is ubiquitous. Related: Microplastics Could Accumulate in Our Brains More Than in Kidneys And Livers "This is the first systematic evidence of how normal and intended use of foodstuffs packaged in plastics can be contaminated with micro- and nanoplastics," Zimmermann told CNN. "We found food packaging is actually a direct source of the micro- and nanoplastics measured in food." The more scientists look into micro- and nanoplastics, or MNPs, the more we see just how widespread they have become. These are tiny pieces of material, too small to see, released by a variety of polymers as they're used or break up in the environment. Plastic is ubiquitous in our modern society, providing a cheap, easily manufactured solution to everything from storage to clothing to furnishings. In recent decades it has become clear its resistance to degrading doesn't mean it is impervious to crumbling into smaller fragments, which easily filter through ecosystems. Studies have found microplastics throughout the human body, including placentas. It's been found in every major organ in mice, including their fetuses. What makes this even more worrying is that we just have very little idea about the health impacts, although it's not looking promising: A study last year found that cardiac and stroke patients with a high concentration of microplastics in their carotid artery plaque had a significantly elevated risk of death. Zimmermann and her colleagues examined 103 studies that have investigated the presence of plastic particles in food and food simulants. From these studies, they extracted 600 entries about food contact articles, of which 96 percent reported the presence of MNPs. Those entries were also compiled into a searchable and filterable dashboard that anyone can access, allowing users to home in on different types of food contact articles, from packaging to baby bottles, as well as different types of plastic. Related: Glass Bottles Actually Contain More Microplastics, Scientists Find Of particular note, the researchers found, is that multiple studies found that for some reusable plastic items, such as melamine bowls, the amount of microplastics shed increased with each wash. This suggests that repeated heating and abrasion increases the rate at which these items degrade. The researchers also note that ultra-processed food contains more microplastic than minimally processed food. The reason for this is simple: more processing steps mean greater exposure to plastic food-processing equipment, resulting in more MNPs in the final product. Their findings, the researchers say, strongly indicate that not only is a lot more research warranted, but also that more needs to be done to minimize the use of plastics in food packaging and preparation. "Our study shows that under intended or foreseeable conditions of use, plastic food contact articles can release MNPs into foodstuffs," they write in their paper. "The contribution of plastic food contact articles to human MNP exposure is currently unclear and warrants further investigation. Further research is also necessary to establish human health impacts associated with MNP exposures, but a precautionary approach aimed at limiting human exposure to MNPs, including from food contact articles, is prudent." You can access the interactive dashboard here, and the paper has been published in npj Science of Food. Your Brain on Speed: Is Watching Video in Fast-Forward Bad For Your Memory? 'Curse of Tutankhamun' Could Hide a Secret Cancer-Fighting Compound Common Vitamin Could Be The Secret to Younger-Looking Skin
Yahoo
8 hours ago
- Yahoo
Scientists Are Finding Microplastics Almost Everywhere In The Body. How Bad Is That, Really?
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." From ocean shores to grocery stores, plastic is all around us. Scientists are even finding microplastics, which are small bits of plastic under five millimeters long, in over half of human organ systems. That may sound scary, but scientists are still figuring out exactly what their presence means—and if they're truly harmful for our long-term health. The good news? 'I don't think we can say yet that [microplastics] are everywhere' because it's such a new area of research, and they're hard to measure, says Kjersti Aagaard, MD, PhD, the medical director of HCA Healthcare Gulf Coast Division and lead clinician at Texas Maternal Fetal Medicine. Plus, some of the spots where they have been detected—like in human stools and urine—show that microplastics can be cleared from the body, meaning they might not stick around in the long run anyway. Meet the experts: Kjersti Aagaard, MD, PhD, is the medical director of HCA Healthcare Gulf Coast Division and lead clinician at Texas Maternal Fetal Medicine. Stephanie Wright, PhD, is a senior lecturer in environmental toxicology at Imperial College London. Eliseo Castillo, PhD, is an associate professor and director of gastroenterology research at the University of New Mexico. Ahead, experts explain how microplastics get into our bodies, how they may affect us, and what this all really means for our health. Microplastics get into your body through food, water, and air, says Stephanie Wright, PhD, a senior lecturer in environmental toxicology at Imperial College London. Given the amount of air humans breathe every day—over 2,000 gallons, per the American Lung Association—inhalation plays a huge role in how microplastics get into the body, she says. By now, it's common knowledge that breathing in smoke, dust, mold, and other kinds of particle pollution are generally bad for your health. Since microplastics are tiny, non-natural particles found in the air, Wright says that they can be considered particle pollution, too. Wright says that microplastics are likely not as toxic as lead, mercury, or the carcinogenic chemicals that come from burning oil, gas, or coal; lead poisoning, for example, causes almost one million deaths per year. Still, they're probably not the best thing to ingest. A recent 2024 study in the New England Journal of Medicine found that patients with a higher amount of microplastics in their carotid artery plaques were at a higher risk of stroke. Right now, there's an emerging correlation—but not necessarily a causation—between microplastics and microvascular (heart) disorders, and between microplastics and inflammation, Aagaard says. So, it's not known whether microplastics are causing the microvascular disorders and inflammation. Another 2025 study in Nature Medicine found about a spoon's worth of microplastics in postmortem brains, and found higher concentrations of microplastics in the brains of those with dementia. However, the relationship between microplastics and dementia is not necessarily causal; because dementia can cause impairment to the blood-brain barrier (thus impacting the brain's ability to keep unwelcome particles out) a higher concentration of microplastics would be expected in the brain anyway, according to the study. In lab studies, throwing microplastics on animal immune and gut cells alters them. It causes oxidative stress, which is a cellular imbalance that can lead to inflammation, says Eliseo Castillo, PhD, an associate professor and director of gastroenterology research at the University of New Mexico and a coauthor of the Nature Medicine study. So far, scientists like Castillo haven't been able to fully determine what this inflammatory effect means for humans. An interesting clue: a 2022 study in Environmental Science & Technology found that stools from participants with inflammatory bowel disease contained a higher concentration of microplastics than those without the disease. But again, that's not to say that this association is causal. While Castillo hasn't seen evidence of microplastics causing inflammation in a healthy human gut, he says it's possible that microplastics could very well exacerbate inflammatory bowel disease. While microplastics have not yet been found in human fetuses, scientists have found them in human placentas. Aagaard, who studies the connections between microplastics and reproductive health, coauthored a 2024 study in Toxicological Sciences that looked at 62 placenta samples and detected microplastics in all of them. In her more recent research, she also discovered that microplastic levels were elevated in placentae from preterm births compared to the placentae of full-term births. While many studies have been done on animals, understanding cause and effect in humans is a bit harder. Mixing microplastics with animal cells in a petri dish is not the same as a human ingesting microscopic amounts of plastic over time, so it may not be an accurate enough way to look at microplastics in our system, says Castillo. The same limitation goes for feeding a lab mouse microplastics for weeks on end and studying the impact on the animal—that isn't how humans ingest microplastics, so those studies may not be super accurate. Plus, it's difficult to keep microplastics out of samples in lab studies, says Castillo. Collection tubes, research instruments, and even air particles can contain microplastics, which can contaminate specimens in the lab. That doesn't mean that plastics aren't in the specimens; it just means that it's hard to be completely certain of microplastic levels when the laboratory is full of microplastic contamination. While researchers figure out the impact of microplastics on our bodies, here are some tips from the experts for minimizing exposure: Don't microwave food in . Doing so can cause millions of microplastic particles to transfer into food, per 2023 research in Environmental Science & Technology. Avoid exposure to tires and traffic. (Not so) fun fact: Car tires are a significant source of microplastic air pollution. However, you can avoid breathing in the small nanoparticles by closing your car windows and avoiding busy roads when you have the option, says Wright. Swap synthetic fibers for natural ones. Given that synthetic fibers in fabrics make up a large amount of microplastics in the environment, Wright suggests replacing synthetic upholsteries, furniture, carpets, and clothing with natural materials (like cotton) to lower your exposure through your skin and airways. Minimize use of plastic water bottles. A liter of bottled water can contain 240,000 tiny particles of plastic, per the National Institutes of Health (NIH). So you may want to invest in a reusable water bottle, especially a metal one. Reduce the amount of you eat. Microplastics have been found in ultra-processed foods due to the processing and packing of the foods, per a 2025 review in Genomic Press. Bisphenol A (BPA) has also been found in plastic food wrappers. Until there's more research on the long-term effects of microplastics on our bodies, you can follow those tips to decrease your exposure—and to reduce your overall plastic pollution while you're at it. After all, using less plastic is better for you, your community, and the planet anyway; it's a win-win. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
Forbes
14 hours ago
- Forbes
This Brazilian Startup Is Turning A Population Of 211 Million Into A Cannabis Data Goldmine
Toninho Corrêa While much of the world watches Germany and the U.S. inch forward on cannabis reform, Brazil has quietly become home to a fast-growing and highly structured medical cannabis market. And helping drive that transformation is a mobile app (not a clinic, cultivator or multinational) that's redefining patient access in one of the world's most complex regulatory environments. It's called Blis, and if you haven't heard of it yet, you're not alone. Built entirely in Brazil by a team of local developers and patients, the platform has already reached more than 300,000 users, generates R$2 million (about $363,000) in monthly revenue and holds what may be the largest real-world cannabis patient database in Latin America. With a population of more than 211 million, Brazil is Latin America's largest potential market for medical cannabis, but also one of the most complex to navigate. Under ANVISA's RDC 660 and RDC 327, cannabis prescriptions are legal, but only for imported, pharmaceutical-grade products, and only with doctor supervision. Despite those constraints, analysts project Brazil's medical cannabis sector could exceed $4.4 billion by 2032, driven by rising demand, decreasing stigma and a worsening mental health crisis. Across the region, Latin America's legal cannabis market is expected to reach $3.75 billion by 2028, with Brazil accounting for a significant share, especially if CBD flower is reauthorized for import in the coming months, opening an entirely new vertical for digital platforms. Born From Patients, Built For Brazil Blis didn't begin in a boardroom; it started with a group of Brazilian patients, frustrated by the painful logistics of getting medical cannabis legally. 'We faced enormous difficulties,' said CEO Toninho Corrêa. 'From the medical consultation to the import bureaucracy.' The existing system was slow, scattered and intimidating. So they built something new: an app approved by both Apple and Google that allows full legal access to cannabis treatment in Brazil, from doctor consultation to home delivery, in just a few taps. According to Corrêa, the platform has reduced access time by 160x, collapsing what used to take weeks into a seamless digital experience. And as cannabis adoption in Brazil shifts from critical conditions like Parkinson's and epilepsy toward broader wellness use (for sleep, anxiety, stress and focus), demand is accelerating. 'In practice, we are creating an entirely new market in Brazil for this type of alternative therapy,' he said. Rather than adapt a foreign model, Blis was built locally from the ground up, with Brazilian regulations, payment systems and patient behavior in mind. 'Importing a foreign model wouldn't work,' Corrêa said. 'We needed a solution tailored to the country's regulatory and cultural context.' That local-first approach has now positioned Blis as a scalable model for the rest of Latin America — and beyond. Numbers That Speak For Themselves In under a year, Blis has surpassed 300,000 downloads and now reaches patients in more than 1,800 cities and towns across Brazil, including many rural areas where medical support is limited or nonexistent. According to the company, over 60% of users who complete a consultation go on to purchase a product. Furthermore, the platform boasts a 42% repurchase rate, signaling strong adherence to treatment plans. Blis App The average order value is around R$1,000 (roughly $182) and the top-selling products are gummies and oils focused on sleep, anxiety and focus, an indicator of Brazil's shifting relationship with cannabis: less taboo, more therapeutic. 'Gummies grew faster than we expected,' Corrêa said, noting their popularity among women aged 30 to 45, who favor discreet, precisely dosed formats. Adoption is also rising among patients over 60, especially for sleep support and chronic pain relief; a demographic often overlooked in global cannabis marketing. 'We're not just seeing growth in the typical early adopter audience. This is mainstream,' he added. A Massive Cannabis Patient Dataset You've Probably Never Heard Of Beyond product sales, Blis is quietly building something even more valuable: data. With over 25,000 real-world patient records and growing, the platform now manages what it claims is one of the largest clinical cannabis databases in Latin America, a resource that could shape treatment standards, support clinical trials and inform regulatory strategy across the region. The company says all data collection follows strict LGPD standards and informed consent protocols. The top three conditions being treated on the platform are insomnia, anxiety and stress, a mental health trifecta that has surged across Brazil in the wake of COVID-19 and ongoing economic instability. Corrêa says the company is now exploring partnerships with researchers and institutions to translate this data into high-impact clinical insights. 'This is a living ecosystem. We're just getting started.' Blis says it handles patient data in full compliance with Brazil's General Data Protection Law (LGPD), using anonymization protocols for any internal studies or aggregated analysis. 'Only authorized professionals have access to patient records, with full traceability and consent controls,' Corrêa noted. While no personal data is currently shared with third parties, Blis may partner with research institutions in the future — but only under strict ethical review and legal safeguards. 'Patients are always informed about how their data is used and can revoke consent at any time,' Corrêa said. Corrêa also noted a sharp rise in interest for gummies, particularly among women and older patients, who value simplicity, discretion and routine. 'We were surprised by how fast that segment matured,' he said. It's a signal that, when designed well, medical cannabis can meet people where they are, without intimidation or stigma. A Market Shaped By Regulation — But Led By Patients From the outside, Brazil's medical cannabis landscape can look impenetrable. But insiders like Corrêa argue that perception no longer matches reality. 'Many still think cannabis is illegal or only accessible in very severe cases,' he said. 'But ANVISA's RDCs 660 and 327 allow legal access with a prescription. The real issue isn't regulation; it's public awareness and access.' In that gap, Blis has positioned itself as both a healthcare facilitator and an information bridge. The company has invested heavily in educational outreach, working with media outlets, conservative audiences and even older patient groups to dispel misconceptions and normalize treatment. 'We made a point of starting Blis' communication through more traditional channels,' Corrêa said. 'That helped us build credibility in places where cannabis was still taboo.' A potential turning point looms: the reauthorization of CBD flower imports, which ANVISA is reportedly considering in the coming weeks. If approved, it would open a new therapeutic category for platforms like Blis, allowing faster-acting, inhalable options for patients with chronic pain, advanced conditions or prior experience with cannabis. 'We're ready,' Corrêa said. 'This would expand our product portfolio and create new experiences for patients who need different kinds of relief.' From Patient App To Platform Play Blis may have started as a fix for a broken access system, but it's now eyeing a far larger opportunity. The company says it hit breakeven within six months, now counts over 25,000 active patients and projects a valuation of over $100 million by year's end, up from roughly $60 million today. The roadmap ahead includes expanding to at least one Latin American market by 2025, launching new technology and service channels, and publishing the company's first clinical data report based on its growing patient base. 'We're building toward a R$1 billion valuation by 2027,' Corrêa said, 'but more importantly, we're building trust.' To reach that next phase, Blis is currently in conversations with investors, strategic partners and scientific collaborators — both in Brazil and internationally. Corrêa says he's open to capital, but only when it aligns with the company's mission. 'What we're looking for is more than money. It's regulatory expertise, clinical insight and the ability to scale responsibly.' Latin America Is Watching Although Blis was built specifically for Brazil's regulatory maze, its model, combining technology, medical guidance and legally compliant distribution, could travel well. 'Blis was built to scale,' Corrêa said. 'Countries like Colombia, Argentina and Mexico are already advancing cannabis regulations, and we see a strong fit for digital platforms that educate and reduce stigma.' Each country brings its own challenges, but the demand patterns — anxiety, insomnia, chronic pain — are strikingly similar across Latin America. Corrêa believes Brazil's unique mix of tight regulations and huge unmet demand has forced innovation in a way that could serve as a template for emerging markets. 'Brazil may lag in public perception, but we lead in digital access,' he said. Compared to countries like Colombia, which has prioritized cultivation, or Mexico, where legal ambiguity continues to stall implementation, Brazil's patient-first approach, anchored in ANVISA oversight and doctor supervision, may prove more scalable in the long term. And while most of the international cannabis spotlight remains focused on North America and Europe, Corrêa is confident: 'The next wave of cannabis innovation may not come from where people expect.' Redefining Wellness, One Click At A Time For Corrêa, cannabis is just the beginning. 'Blis is not just a cannabis company: it's a new model of wellness for Latin America,' he said. The platform's long-term vision includes expanding into personalized protocols, new therapeutic categories, and broader public health integration, all grounded in real-world data and patient experience. As mental health needs grow and healthcare systems strain under demand, platforms like Blis are positioning themselves not just as dispensers of product, but as scalable infrastructure for care. 'The debate is no longer led by regulators,' Corrêa said. 'It's led by patients.' Blis may not have brand recognition in North America — yet — but its trajectory offers a glimpse of what cannabis innovation can look like when it's rooted in need, built with purpose, and shaped by the realities of the people it serves.
